CoChat

Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma

Mak, Lung-Yi, Cruz-Ramón, Vania, Chinchilla-López, Paulina, Torres, Harrys A., LoConte, Noelle K., Rice, John P., Foxhall, Lewis E., Sturgis, Erich M., Merrill, Janette K., Bailey, Howard H., Méndez-Sánchez, Nahum, Yuen, Man-Fung, Hwang, Jessica P. · 2018 · American Society of Clinical Oncology Educational Book
Cited by 237

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

The incidence rate of hepatocellular carcinoma (HCC) is rising. It is one of the most common cancers worldwide and accounts for substantial morbidity and mortality. Chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, and nonalcoholic fatty liver disease (NAFLD) are the most important etiologies of HCC, and effective screening and management strategies are crucial to reduce the HCC risk. For HBV, which accounts for the majority of HCC cases, most infections were acquired via perinatal and early horizontal transmission. Universal vaccination of newborns has led to a decline in HCC incidence compared with the pre-vaccination era. Effective antiviral therapies with nucleos(t)ide analogues or pegylated interferon reduced the incidence of HCC. For HCV, the emergence of effective direct-acting antiviral (DAA) agents has substantially improved cure rates; therefore all patients with HCV should be considered for DAA treatment. The most important obstacle in eliminating HCV is access to therapy. For NAFLD, the global incidence is increasing rapidly, thus its impact on HCC incidence may be explosive. Progression to HCC in NAFLD happens particularly in those with nonalcoholic steatohepatitis (NASH) and exacerbated by metabolic syndrome, or PNPLA3 gene polymorphism. Lifestyle changes are imperative while drug therapy has yet to demonstrate substantive protective effects on HCC prevention. For management of HCC, early diagnosis via imaging surveillance among persons with HCC risk factors remains the most important strategy to identify early-stage disease appropriate for resection or transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/edbk_200939

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 237

Metadata

Authors
Mak, L.-Y., Cruz-Ramón, V., Chinchilla-López, P., Torres, H. A., LoConte, N. K., Rice, J. P., Foxhall, L. E., Sturgis, E. M., Merrill, J. K., Bailey, H. H., Méndez-Sánchez, N., Yuen, M.-F., & Hwang, J. P.
Venue
American Society of Clinical Oncology Educational Book
Published
2018-05
Volume
38
Issue
38
Pages
262-279
ISSN
  • 1548-8748 (ISSN-L)
  • 1548-8756
OpenAlex
W2806541405
Cited by
237
References
16
FWCI
13.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1200/edbk_200939
The paper
Mak, L.-Y., Cruz-Ramón, V., Chinchilla-López, P., Torres, H. A., LoConte, N. K., Rice, J. P., Foxhall, L. E., Sturgis, E. M., Merrill, J. K., Bailey, H. H., Méndez-Sánchez, N., Yuen, M.-F., & Hwang, J. P. (2018). Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_200939

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.